Chinese Japanese Germany Korea


Ritonavir structure
Chemical Name:
Norvi;CS-477;RITONA;Norvir;A 84538;ABT-538;Ritonavi;RITONAVIR;litonavir;Ritonavire
Molecular Formula:
Formula Weight:
MOL File:

Ritonavir Properties

Melting point:
Boiling point:
947.0±65.0 °C(Predicted)
1.239±0.06 g/cm3(Predicted)
Flash point:
storage temp. 
-20°C Freezer
DMSO: soluble10mg/mL (clear solution, warmed)
white to beige
Water Solubility 
CAS DataBase Reference
155213-67-5(CAS DataBase Reference)
NCI Dictionary of Cancer Terms
Norvir; ritonavir
  • Risk and Safety Statements
Signal word  Danger
Hazard statements  H225-H302+H312+H332-H319
Precautionary statements  P210-P280-P305+P351+P338-P261-P301+P312+P330-P302+P352+P312-P304+P340+P312
Hazard Codes  Xi,Xn
Risk Statements  36/38-20/21/22-41
Safety Statements  26-37/39-36/37-39
RIDADR  UN 1648 3 / PGII
WGK Germany  3
RTECS  XA5310000
HS Code  29341000

Ritonavir price More Price(9)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich PHR1734 Ritonavir 155213-67-5 1g $86.2 2019-12-02 Buy
Sigma-Aldrich 1604803 Ritonavir United States Pharmacopeia (USP) Reference Standard 155213-67-5 200mg $352.8 2019-12-02 Buy
Cayman Chemical 13872 Ritonavir ≥98% 155213-67-5 50mg $187 2020-06-24 Buy
Cayman Chemical 13872 Ritonavir ≥98% 155213-67-5 10mg $44 2020-06-24 Buy
Sigma-Aldrich SML0491 Ritonavir ≥98% (HPLC) 155213-67-5 10mg $60.8 2019-12-02 Buy

Ritonavir Chemical Properties,Uses,Production


Norvir was launched in Germany, the UK and US for treatment of advanced HIV in combination with antiretroviral nucleoside analogs in a record 72 days by the FDA. It is an inhibitor of HIV aspartic protease which is critical in the processing of a propeptide into the gag, gag-pol gene products and the protease itself. This inhibition results in the release of non-infectous immature virus particles. It is greater than 500-fold more selective for viral aspartic protease than the human version, has good oral bioavailability and may increase the bioavailability of other protease inhibitors. Ritonavir was able to increase the CD4 and CD8 lymphocyte count as well as reduce viral RNA. It is more potent than saqunavir and comparible in potency to zidovudine and lamivudine.

Chemical Properties

White or almost white powder.


Abbott (USA)


Protease inhibitor; antiviral (HIV).


Ritonivir is an HIV protease inhibitor (EC50 = 25 nM) that also inhibits CYP3A4, the primary cytochrome P450 isoform that metabolizes protease inhibitors. Through CYP3A4 inhibition, low doses of ritonivir can reduce the metabolism of concomitantly administered protease inhibitiors, enhancing their bioavailability and efficacy.[Cayman Chemical]


A selective HIV protease inhibitor


ChEBI: An L-valine derivative that is an antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.


Although ritonavir (Norvir) is a potent inhibitor of HIV-1 and HIV-2 protease, it is not well tolerated in higher doses. It is mainly used in low doses to increase blood levels of other protease inhibitors and to extend their dosing interval. Ritonavir is more commonly associated with gastrointestinal side effects, altered taste sensation, paresthesias, and hypertriglyceridemia than are other protease inhibitors. Pancreatitis may occur in the presence or absence of hypertriglyceridemia.

brand name

Norvir (Abbott).

Antimicrobial activity

Ritonavir is active against HIV-1 and, to a lesser extent, HIV-2.

Acquired resistance

At antiretroviral doses resistance is associated with the presence of specific amino acid substitutions in the HIV protease at positions 82 and 84. Concern about the risk for selection of ritonavir resistance when used at a subtherapeutic ‘booster’ dose has so far not been borne out by clinical experience.

Pharmaceutical Applications

A synthetic chemical available for oral use as soft capsules and a liquid formulation. It is now almost exclusively used as a pharmacokinetic enhancer to ‘boost’ the pharmacokinetic properties of HIV protease inhibitors in the treatment of HIV-1 infection in patients over 1 month in age.

Mechanism of action

Because of the strong CYP450-inhibiting effects of ritonavir, the drug has found value when used in fixed-dosage combinations with other PIs to block their metabolism and act as a booster for these drugs (lopinavir/ritonavir and tipranavir/ritonavir). In these cases, ritonavir is used in a subtherapeutic dose but boosts the effectiveness of the coadministered drug. The utilization of ritonavir in a therapeutic dose for treating HIV infections appears to be decreasing, but its utilization as a booster drug is finding favor.


Oral absorption: Not known/available
Cmax 600 mg twice daily: c. 11.2 mg/L
Cmin 600 mg twice daily: c. 3.7 mg/L
Plasma half-life: c. 3–5 h
Volume of distribution: c. 0.3–0.6 L/kg
Plasma protein binding: c. 97%
Absorption and distribution
Fasting and high-fat meals had no appreciable effect on oral absorption. It penetrates poorly into the CNS. The semen:plasma ratio is <0.04. It is distributed into breast milk.
Metabolism and excretion
Four oxidized metabolites have been identified, the major of which retains antiretroviral activity. Around 11% of the dose is excreted in urine, 4% as unchanged drug. The remainder is found in feces. Metabolites are eliminated primarily via the feces.
No dose adjustment is recommended in mild to moderate hepatic impairment. It should not be given to patients with severe hepatic impairment, nor should it be given as a pharmacokinetic enhancer to patients with decompensated liver disease.

Clinical Use

Treatment of HIV infection in adults and children >1 month old (in combination with other antiretroviral agents)

Side effects

Full (antiretroviral) doses are associated with nausea, vomiting, diarrhea and fatigue in >20% of subjects. The degree to which ritonavir at low dose is associated with specific adverse events is uncertain. In HIV-negative healthy volunteers given ‘booster’ doses of 100 mg every 12 h, the concentration of total cholesterol, low-density cholesterol and triglycerides all increased, and the concentration of high-density cholesterol concentration fell.

Ritonavir Preparation Products And Raw materials

Raw materials

Preparation Products

Ritonavir Suppliers

Global( 316)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
18627774460 CHINA 743 58
0086-13720134139 CHINA 968 58
BOC Sciences
1-631-619-7922 1-631-619-7922
1-631-614-7828 United States 20039 58
Shenzhen Nexconn Pharmatechs Ltd
15013857715 CHINA 3000 58
Alpha Biopharmaceuticals Co., Ltd
0086-411-39042693 China 921 58
Capot Chemical Co.,Ltd.
+86(0)13336195806 +86-571-85586718
+86-571-85864795 China 19929 60
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 22625 55
career henan chemical co
+86-371-86658258 CHINA 30043 58
Shaanxi Yikanglong Biotechnology Co., Ltd.
17791478691 CHINA 297 58
Chemwill Asia Co.,Ltd.
86-21-51861608;;; CHINA 23977 58

Related articles

View Lastest Price from Ritonavir manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2020-06-18 Ritonavir
US $10.00 / g/Bag 1Kg/Bag Above 99% 5000kg/month Shijiazhuang Suking Biotechnology Co .,Ltd. Co., Ltd.
2020-05-13 Ritonavir
US $288.00 / g 1g ≥98% 10kg BOC Sciences
2020-04-30 Ritonavir
US $0.01-1.00 / KG 1KG 99% 50 tons Shaanxi Dideu Medichem Co. Ltd

155213-67-5(Ritonavir)Related Search:

Copyright 2017 © ChemicalBook. All rights reserved